SAN DIEGO–(BUSINESS WIRE)–Oct. 3, 2003–IDEC Pharmaceuticals Corporation (NASDAQ:IDPH), a leader in the commercialization of targeted imunotherapies, will hold its quarterly conference call to discuss third quarter results and 2003 outlook on Tuesday, October 14, 2003, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
This call is being webcast by CCBN and can be accessed at IDEC’s web site at idecpharm.cdmail.biz.
The webcast is also being distributed over CCBN’s Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN’s individual investor center at www.fulldisclosure.com or by visiting any of the investor sites in CCBN’s Individual Investor Network. Institutional investors can access the call via CCBN’s password-protected event management site, StreetEvents (www.streetevents.com).
IDEC Pharmaceuticals Corporation is a leader in the discovery, development, and commercialization of targeted immunotherapies for the treatment of cancer and autoimmune diseases. IDEC discovered and developed the first commercially available radioimmunotherapy product (Zevalin(TM)) approved in the United States, which is used to treat certain non-Hodgkin’s lymphomas. IDEC also discovered, and with co-promotion partner Genentech, Inc., developed the first monoclonal antibody product (Rituxan((R)) approved in the United States for the treatment of cancer. Rituxan is approved in over 70 countries worldwide and is also used to treat various types of non-Hodgkin’s lymphomas. IDEC is a San Diego based, integrated biopharmaceutical company with multiple products in clinical stage development and strategic alliances in a variety of research platforms.
CONTACT: IDEC Pharmaceuticals Vince Reardon, 858-431-8656 Vreardon@idecpharm.cdmail.biz SOURCE: IDEC Pharmaceuticals